Prostate cancer preferentially metastasizes to bone and the mortality from prostate cancer is 70% once bone metastases are present. In addition, prostate cancer-induced bone metastases are associated with significant complications including severe pain, skeletal fractures, spinal cord compression and bone marrow suppression. Most doctors structure their treatment protocols against bone metastases by treating the cancer [...]
At the recent American Association of Cancer Researchers (AACR,) there was a shocking poster presentation that demonstrated that mice that exercised experienced implanted prostate cancer tumor grow that was twice as fast than did those mice who were restricted from exercising! The study was conducted by the Duke Comprehensive Cancer Center (DCCC) and the Duke [...]
Taxotere (chemotherapy for prostate cancer) is administered intravenously usually in an cancer center or a hospital setting. Often the areas which are designated for chemo administration are referred to as infusion centers. Taxotere is administered with either on a higher dosage schedule of once every three weeks (q3wk) or a lower dosage schedule of once [...]
The current standard of care in the treatment of prostate cancer is to use chemotherapy (Taxotere) only in late stage hormone refractory prostate cancer. Most other cancers use chemotherapy agents at a much earlier stage then used for prostate cancer. Prostate cancer cells divide at a rate that is not much faster than normal cell [...]
Many of us think that chemotherapy for prostate cancer only involves the use of Taxotere. Just for the sake of accuracy, I want to clarify that almost every drug we take to treat prostate cancer is chemotherapy. Chemotherapy drugs are the drugs that are designed to kill cells. All of the drugs used as a [...]